Navigation Links
NewCardio Announces Positive Results From Third Clinical Validation Study
Date:8/13/2008

Test validates QTinno(TM) - proves the ability to automatically measure QT

intervals in even challenging samples

SANTA CLARA, Calif., Aug. 13 /PRNewswire-FirstCall/ -- NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic and services company, today revealed the results of its third external validation study of QTinno(TM) (the "NCE3 Study"). The study was led by an independent industry leading cardiac safety expert with extensive experience in pharmaceutical clinical trials. The study evaluated the accuracy, precision and speed of NewCardio's lead product, QTinno(TM), in producing fully automated measurements of drug-induced QT prolongation, a key cardiac safety indicator. Such data is now required by drug regulatory bodies worldwide for all new drugs in development, and at present must be obtained by expensive and time-consuming manual or semi-automated methods.

The NCE3 study was a randomized, blinded study of more than 2,500 digital ECGs acquired from healthy research subjects treated with either placebo or a cardiac drug with significant QT-prolonging properties and a known propensity to cause serious cardiac arrhythmias. QT intervals were determined on all study ECGs by QTinno(TM) and by the current "gold standard" approach: careful manual reading by a single cardiologist with extensive expertise and experience in ECG evaluation. The primary endpoint, time-matched, placebo-controlled QT prolongation induced by drug, was chosen because drug-induced QT prolongation is the primary parameter that regulatory bodies evaluate to assess the cardiac arrhythmia risk of a new drug candidate.

Results from the NCE3 study showed that QTinno(TM) was accurate in measuring drug-induced QT prolongation. The automated determination derived at by QTinno(TM) and the "gold standard" manual measurement were virtually identical (well under 1 millisecond difference), and individual measurements showed a high degree of precision (
'/>"/>

SOURCE NewCardio, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
2. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
3. Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma
4. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
5. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
6. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
7. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
8. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
9. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
10. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
11. Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014  BioPontis Alliance for Rare Disease ... announced today the creation of a joint venture ... the rare disease known as Charcot- Marie-Tooth (CMT) ... model earlier this month. Today,s partnership announcement with ... model where researchers and all CMT dedicated organizations ...
(Date:10/19/2014)... 2014 Große Pharmafirmen werden ... Problem dabei ist, dass große Pharmafirmen nicht willens ... teilen. Es war deshalb nicht einfach, ... umso mehr, dass es uns gelungen ist! Wir ... aufzuschreiben - mit einem Vorbehalt - einige haben ...
(Date:10/17/2014)... Oct. 17, 2014  Hanger, Inc. (NYSE: ... its results of operations for the quarter ended September ... market closes.  A conference call to discuss these results ... Friday, November 7, 2014. Those wishing to participate should ... November 14, 2014 by dialing 1-855-859-2056 and referencing Conference ...
Breaking Medicine Technology:The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3Vergleichsbericht zu Pharma-Kühlketten und CRT 2
... and CEO of Curemark, LLC , ( www.curemark.com ), ... of neurological diseases, moderated the neuroscience roundtable focused on autism ... Hauppauge, New York.   Sponsored by the State ... and Cold Spring Harbor Laboratories, the Life Sciences Summit focused ...
... Oct. 11 BioStorage Technologies, a global leader ... storage for the pharmaceutical and biotechnology industries, has ... sample preparation services, including sample aliquoting and nucleic ... need for comprehensive sample management continues to grow, ...
Cached Medicine Technology:Curemark Moderates Autism Panel at Life Sciences Summit 2010 2Curemark Moderates Autism Panel at Life Sciences Summit 2010 3Industry Leader BioStorage Technologies Broadens Sample Management Operations to Include Laboratory Sample Preparation Services 2
(Date:10/20/2014)... Collins, CO (PRWEB) October 20, 2014 ... dGH assays are the only imaging assays capable ... in a single test.  With these three dimensions ... their ability to detect the widest range of ... translocations—mutations usually missed by other genomic tools, including ...
(Date:10/20/2014)... It’s hard to imagine what it’s like to live without ... world, it’s a reality. And while new shoes are considered ... walk barefoot on rocky terrain or sewage-lined streets just to ... , Buckner International's Shoes for Orphan Souls ... to encourage support for Air1 and while also providing new ...
(Date:10/19/2014)... Hastings and Hastings, a Phoenix personal injury law ... greater Phoenix area and across Arizona reports record demand ... automobile accidents. Statistics have indicated a steady increase in ... such, Hastings and Hastings has seen a steady increase ... have been injured through no fault of their own ...
(Date:10/19/2014)... 20, 2014 This report provides ... Seizure, complete with comparative analysis at various stages, ... (MoA), route of administration (RoA) and molecule type, ... press releases. It also reviews key players involved ... special features on late-stage and discontinued projects. , ...
(Date:10/19/2014)... October 20, 2014 SweetDressy.com, a professional ... announced its promotion for long evening dresses . ... the special offer; the current discount is up to ... the industry pioneers in the fashion field. Its dress ... ladies dwelling in various parts of the world. All ...
Breaking Medicine News(10 mins):Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2
... News) -- Smoking boosts the risk of rheumatoid arthritis in ... risk factor for rheumatoid arthritis are among those most likely ... Researchers evaluated 605 black patients with rheumatoid arthritis and ... disease were slightly more likely to be former or current ...
... , MONDAY, Nov. 29 (HealthDay News) -- Genetics influence ... factors have the greatest impact in the summer, the results ... needed to maintain health and for strong bones, is naturally ... do not contain vitamin D unless it,s added by fortification. ...
... Neuroscientists at the Centre for Addiction and Mental Health (CAMH) ... type of highly targeted treatment for depression with a low ... time in their lives and is a leading cause of ... Nature Medicine found that coupling between two dopamine ...
... with GE Healthcare has produced the first results in humans ... presence and aggressiveness of prostate tumors in real time, by ... researchers have used this technology to conduct real-time metabolic imaging ... assessing the precise outlines of a tumor, its response to ...
... Mozes HealthDay Reporter , MONDAY, Nov. 29 (HealthDay ... tool is surging in emergency departments across the United States, ... to 2007, CT scan use in ERs increased by nearly ... concerns about the potential risks posed by more frequent exposure ...
... personal history of breast cancer should consider annual screening ... study presented today at the annual meeting of the ... Cancer Society (ACS) guidelines currently recommend annual screening with ... or with a strong family history indicating a lifetime ...
Cached Medicine News:Health News:Heavy Smoking May Double Rheumatoid Arthritis Risk in Blacks 2Health News:Neurological protein may hold the key to new treatments for depression 2Health News:New prostate cancer imaging shows real-time tumor metabolism 2Health News:New prostate cancer imaging shows real-time tumor metabolism 3Health News:New prostate cancer imaging shows real-time tumor metabolism 4Health News:CT Scan Use Surging in Hospital ERs 2Health News:CT Scan Use Surging in Hospital ERs 3Health News:CT Scan Use Surging in Hospital ERs 4Health News:Women with personal history of breast cancer should be screened with MRI 2
Antiseptic - Antibacterial Sudsing Cleanser...
... This requiring no water for ... hand hygiene to physically clean ... is either not an option ... allows you to return to ...
BETASEPT® Scrub 4% is for surgical handscrubbing, healthcare personnel hand-washing, preoperative patient prepping and general skin degerming....
... Scrub Care® Brand soaps, emulsions, washes ... ultimate in healthy skin care, helping ... skin healthy and soft even with ... not contain petroleum-based substances that can ...
Medicine Products: